Consolidated Balance Sheets [Abstract] Total current assets Total assets Total current liabilities Total liabilities Total stockholders’ equity Beginning balance Ending balance Total liabilities and stockholders’ equity Total operating expenses Operating loss Total other (expense) income Net loss Net loss Net income (loss) Consolidated Statements of Stockholders’ Equity [Abstract] Beginning balance (in Shares) Ending balance (in Shares) Common stock outstanding (in Shares) Sale of Stock [Axis] Equity Components [Axis] Net cash used in operating activities Net cash used in investing activities Net cash provided by financing activities Net decrease in cash, cash equivalents and restricted cash and cash equivalents Cash, cash equivalents and restricted cash and cash equivalents—beginning of period Cash, cash equivalents and restricted cash and cash equivalents—end of period Cash, cash equivalents and restricted cash Condensed Consolidated Statements of Operations [Abstract] Other income, net Condensed Consolidated Statements of Cash Flows [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Restructuring and Related Activities [Abstract] Accounting Policies [Abstract] Long-Lived Asset, Class [Axis] Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] Fair Value Disclosures [Abstract] Cash and Cash Equivalents [Axis] Total assets Total liabilities Fair Value Hierarchy and NAV [Axis] Balance at beginning of period Balance at end of period Total property and equipment, net Property and equipment, net Total accrued expenses and other current liabilities Accrued expenses and other current liabilities Debt Disclosure [Abstract] Net carrying amount of note payable Debt Instrument [Axis] Long-Term Debt, Type [Axis] Total interest expense Interest expense Class of Stock [Axis] Share-Based Payment Arrangement [Abstract] Award Type [Axis] Outstanding at beginning of period (in shares) Outstanding at end of period (in shares) Weighted-Average Exercise Price - Outstanding at beginning of period (in usd per share) Weighted-Average Exercise Price - Outstanding at end of period (in usd per share) Commitments and Contingencies Disclosure [Abstract] Total Total future minimum lease payments Income Tax Expense (Benefit) (in Dollars) Effective income tax rate Deferred tax assets Deferred tax assets Deferred tax liabilities Net deferred taxes Antidilutive Securities [Axis] Adjusted net loss Weighted-average common stock outstanding, diluted (in Shares) Weighted-average common shares outstanding, diluted (in Shares) Segments [Axis] Strategic Review and Liquidity [Abstract] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Earnings Per Share [Abstract] Segment Reporting [Abstract] Restructuring Type [Axis] Restructuring Reserve [Roll Forward] Balance at beginning of period Balance at Ending of period Document Type Entity Registrant Name Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Ex Transition Period Entity Central Index Key Amendment Flag Assets Current assets: Cash and cash equivalents Cash and cash equivalents (in Dollars) Prepaid expenses and other current assets Restricted cash and cash equivalents Operating lease right of use asset Other assets Liabilities and stockholders’ equity Current liabilities: Accounts payable Operating lease liability, current Note payable, current, net of discount and issuance costs Note payable, net of discount and issuance costs Operating lease liability, net of current portion Note payable, net of discount, issuance costs, and current portion Derivative liability Commitments and contingencies Stockholders’ equity: Preferred stock, $0.0001 par value, 5,000,000 shares authorized as of December 31, 2025 and 2024; no shares issued or outstanding as of December 31, 2025 and 2024 Preferred stock, $0.0001 par value, 5,000,000 shares authorized as of June 30, 2026 and December 31, 2025; no shares issued or outstanding as of June 30, 2026 and December 31, 2025 Preferred stock par value (in Dollars per share) Preferred stock authorized (in Shares) Preferred stock authorized (in shares) | shares Preferred stock issued (in Shares) Preferred stock issued (in shares) | shares Preferred stock outstanding (in Shares) Preferred stock outstanding (in shares) | shares Common stock, $0.0001 par value, 200,000,000 shares authorized as of December 31, 2025 and 2024; 48,596,817 and 44,827,159 shares issued and outstanding as of December 31, 2025 and 2024, respectively Common stock, $0.0001 par value, 200,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 48,599,066 and 48,596,817 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively Common stock par value (in Dollars per share) Common stock authorized (in Shares) Common stock authorized (in shares) | shares Common stock issued (in Shares) Additional paid-in capital Accumulated deficit Revenue: Collaboration revenue Operating expenses: Research and development General and administrative Other (expense) income: Interest income Loss on extinguishment of debt Loss on extinguishment of note payable Loss on extinguishment of debt Loss on extinguishment of note payable Net loss per common share, basic (in Dollars per share) Net income (loss) per common share, basic (in Dollars per share) Net loss per common share, diluted (in Dollars per share) Net income (loss) per common share, diluted (in Dollars per share) Weighted-average common shares outstanding, basic (in Shares) Weighted-average common stock outstanding, basic (in Shares) Issuance of common stock from at the market offering, net of issuance costs (in Shares) Issuance of common stock from at the market offering, net of issuance costs (in shares) | shares Issuance of common stock from at the market offering, net of issuance costs Issuance costs Stock-based compensation expense Stock option exercises (in Shares) Exercised (in shares) Stock option exercises (in shares) Stock option exercises Operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation expense Depreciation expense Non-cash interest expense Non-cash lease expense Changes in operating assets and liabilities: Accounts payable, accrued expenses and other liabilities Deferred revenue Operating lease liability Investing activities: Financing activities: Proceeds from at the market offering of common stock, net of issuance costs Proceeds from at the market offering of common stock, net of issuance costs (in Dollars) Proceeds from drawdown of term loans Proceeds from issuances under Employee Stock Purchase Plan Proceeds from stock option exercises Supplemental disclosure of cash flow information: Cash paid for interest Supplemental disclosure of non-cash investing and financing activities: Issuance costs in accounts payable and accrued expenses Fair value of derivative liability issued with term loan Assets Current assets: Liabilities and stockholders’ equity Current liabilities: Stockholders’ equity: Revenue: Operating expenses: Other expense: Proceeds from sale of property and equipment Reconciliation of cash, cash equivalents and restricted cash and cash equivalents to the condensed consolidated balance sheets Restricted cash and cash equivalents Adjustment to right of use asset in exchange for reduction in lease liability Interest expense Interest expense Change in fair value of derivative liability Prepaid expenses and other assets Other receivables Purchases of property and equipment Payment of debt issuance costs Payment of debt issuance costs Repayment of term loan Loss on sale and disposal of property and equipment, net Gain on modification of lease liability Gain on modification of lease liability Repayment of note payable and extinguishment costs Market Offering Common Stock Additional Paid-in Capital Accumulated Deficit Nature of Business Strategic Review and Liquidity Basis of Presentation and Summary of Significant Accounting Policies Schedule of Cash and Cash Equivalents Schedule of Property, Plant and Equipment Estimated useful life (in years) Collaboration and License Agreement Financial Instruments and Fair Value Measurements